Skylark Bio

News

Skylark Bio has dosed the first patient in a phase 1/2 trial of SKY-GJB2, a gene therapy for the most common form of genetic deafness in children.

News

In a handful of strongly-worded warning letters, the FDA is cracking down on sales of unapproved peptides - even if they're labelled for research.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.